The company was one of CSE’s projects in the year of 2001 and the technology is a patented delivery platform, based on pentane-1,5-diol, for improving dermal delivery of topically applied pharmaceuticals. Ambria’s intellectual property position is built on several patent families (granted patents as well as pending patent applications), in-licensed rights and product trademarks.
Ambria currently has several products under development, primarily pre-clinical, where two products have undergone early clinical testing.
The technology will initially be deployed in products addressing significant unmet medical needs in large patient groups such as the treatment of multi-resistant bacteria, infected atopic dermatitis, psoriasis and exzema. Another potential use of the platform is the cosmetic market for treating dry skin and dandruff.
